NCT03175497View on ClinicalTrials.gov

Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 25, 2017

Primary Completion Date

August 15, 2018

Study Completion Date

August 15, 2018

Conditions
Solid Tumor, Adult
Interventions
DRUG

Telatinib Mesylate

Telatinib mesylate tablets will be administrated twice a day orally

Trial Locations (1)

Unknown

Fudan University, Zhongshan Hospital, Shanghai

Sponsors
All Listed Sponsors
collaborator

Fountain Medical Development Co., Ltd.

INDUSTRY

lead

Taizhou EOC Pharma Co., Ltd.

INDUSTRY

NCT03175497 - Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter